GEN1106 Clinical Trials (2026): 1 Studies for Solid Tumors & Urothelial Carcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 GEN1106 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Solid Tumors & Urothelial Carcinoma) and 103 total planned enrollment. 1 GEN1106 clinical trial is actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT07416123 (Jun 2029).
Where to Participate: All GEN1106 Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting GEN1106trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| NY | START New York Long Island LLC | Lake Success11042 | NCT07416123 | Map |
| SC | Carolina Urologic Research Center | Myrtle Beach29572 | NCT07416123 | Map |
| TX | South Texas Accelerated Research Therapeutics | San Antonio78229 | NCT07416123 | Map |
GEN1106 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting GEN1106 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | P1 | Solid Tumors | 103 | Apr 2026 |
All GEN1106 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | P1 | recruiting | 103 | Genmab | Apr 2026 |
GEN1106 clinical trials: frequently asked questions
- How many GEN1106 clinical trials are there?
- 1 GEN1106 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are GEN1106 clinical trials recruiting in 2026?
- Yes — 1 GEN1106 trial is actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is GEN1106 being studied for?
- GEN1106 is being studied for Solid Tumors, Urothelial Carcinoma. The trials are grouped by indication on this page.
- What phase is GEN1106 in?
- GEN1106 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors GEN1106 clinical trials?
- The lead sponsor across the most GEN1106 trials is Genmab. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming GEN1106as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: